Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives $25.69 Average Target Price from Analysts

Posted by Brian Himes on Sep 21st, 2026

Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report) has received a consensus recommendation of “Hold” from the twenty research firms that are presently covering the company, MarketBeat reports. Six investment analysts have rated the stock with a sell recommendation, five have given a hold recommendation and nine have issued a buy recommendation on the company. The average 12-month target price among analysts that have covered the stock in the last year is $25.6875.

Several brokerages have commented on SRPT. Zacks Research upgraded shares of Sarepta Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th. Wall Street Zen lowered shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Piper Sandler reduced their target price on shares of Sarepta Therapeutics from $23.00 to $20.00 and set a “neutral” rating for the company in a report on Thursday, July 9th. HC Wainwright restated a “buy” rating on shares of Sarepta Therapeutics in a research report on Tuesday, July 28th. Finally, Wolfe Research upgraded shares of Sarepta Therapeutics from a “peer perform” rating to an “outperform” rating and set a $27.00 target price for the company in a research report on Thursday, July 9th.

View Our Latest Research Report on Sarepta Therapeutics

Sarepta Therapeutics Price Performance

Sarepta Therapeutics stock opened at $20.11 on Friday. The business’s 50-day simple moving average is $18.62 and its two-hundred day simple moving average is $18.67. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.62 and a current ratio of 4.42. The company has a market cap of $2.12 billion, a PE ratio of -6.93, a PEG ratio of 0.29 and a beta of 0.27. Sarepta Therapeutics has a fifty-two week low of $14.68 and a fifty-two week high of $25.32.

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $0.42. The firm had revenue of $401.25 million during the quarter, compared to analysts’ expectations of $366.39 million. Sarepta Therapeutics had a negative return on equity of 1.60% and a negative net margin of 13.48%.The company’s revenue for the quarter was down 34.3% compared to the same quarter last year. During the same period last year, the business posted $2.02 earnings per share. Equities analysts anticipate that Sarepta Therapeutics will post 3.53 EPS for the current year.

Hedge Funds Weigh In On Sarepta Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. acquired a new stake in Sarepta Therapeutics during the second quarter worth about $341,339,000. First Trust Advisors LP lifted its holdings in Sarepta Therapeutics by 107.6% in the first quarter. First Trust Advisors LP now owns 4,135,788 shares of the biotechnology company’s stock valued at $89,995,000 after acquiring an additional 2,143,211 shares during the period. Erste Asset Management GmbH lifted its holdings in Sarepta Therapeutics by 1.6% in the fourth quarter. Erste Asset Management GmbH now owns 2,728,945 shares of the biotechnology company’s stock valued at $58,727,000 after acquiring an additional 43,000 shares during the period. Bank of America Corp DE boosted its position in Sarepta Therapeutics by 26.6% in the 1st quarter. Bank of America Corp DE now owns 2,145,926 shares of the biotechnology company’s stock worth $46,695,000 after purchasing an additional 450,336 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its position in Sarepta Therapeutics by 43.6% in the 1st quarter. Renaissance Technologies LLC now owns 1,665,078 shares of the biotechnology company’s stock worth $36,232,000 after purchasing an additional 505,500 shares in the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

(Get Free Report)

Sarepta Therapeutics, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. Its research platforms include RNA-based technologies, gene therapy and gene-editing approaches designed to address the underlying causes of genetic disorders.

The company’s primary commercial focus has been Duchenne muscular dystrophy (DMD). Sarepta markets Exondys 51, Vyondys 53 and Amondys 45, exon-skipping therapies for eligible patients with specific genetic mutations, as well as Elevidys, a gene therapy developed to treat certain patients with DMD.